Big Board Biotech Stocks in Play This Week
Coral Gables, FL / ACCESSWIRE / October 28, 2014 / CytRx Corporation (NASDAQ: CYTR) announced that a paper, titled “A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma,” has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society.
The paper discusses results from CytRx’s completed Phase 1b/2 clinical trial where 25 patients were enrolled, including 17 patients (68%) with advanced soft tissue sarcoma (STS). Data from the trial demonstrated that aldoxorubicin administered at its maximum tolerated dose (MTD) of 350mg/m2 showed a substantial increase in median progression-free survival (PFS) in patients with advanced STS (n=13). Partial responses (PR) were achieved in 38% of patients and stable disease (SD) was achieved in 46% of patients. Median PFS was 11.25 months and median overall survival (OS) was 21.71 months. Notably, 12 of the 13 patients in the MTD dosing cohort had received prior chemotherapy and had experienced either no response or disease progression while on prior therapy. In addition, patients in this dosing cohort completed a median of 8 dosing cycles, and 9 patients (69%) had a PR or SD lasting 4 months. Aldoxorubicin was generally well tolerated, with no clinically significant cardiotoxicities and no drug-related deaths.
Find out what could be the best investor’s move when it comes to CYTR by getting the complete report here or by cutting and pasting the following link in your Web browser: http://www.pennystockhub.com/
Pacific Biosciences of California, Inc., (NASDAQ: PACB) announced that SLPC has established a new genomics facility with 1,500 square meters of laboratory space in the Tianjin Dong Li Lake Technology Park, dedicated to using PacBio Single Molecule, Real-Time (SMRT(R)) Sequencing as the major sequencing platform for its translational medicine research projects.
“Our goal is to become an innovative high-tech enterprise,” stated founder and CEO of SLPC, Dr. Zhang Yaozhou. “I believe that PacBio’s platform provides the most complete and accurate sequencing data, and we are committed to applying this technology toward the improvement of human health.” SLPC purchased four PacBio RS II Sequencing Systems earlier this year and recently installed them at their newly dedicated facility. The company ultimately intends to focus on applications such as molecular-based approaches for early diagnosis of cancers, disease recurrence control and drug efficacy evaluation.
Find out what could be the best investor’s move when it comes to PACB by getting the complete report here or by cutting and pasting the following link in your Web browser: http://www.pennystockhub.com/.
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,846,976. The patent, which expires in 2024, claims a method of treating hyperphosphatemia comprised of administering a therapeutically effective amount of an orally administrable form of Ferric Citrate to a subject, wherein the orally administrable form is prepared from a ferric citrate active pharmaceutical ingredient having an intrinsic dissolution rate of at least 1.88/mg/cm2/min. In addition, U.S. Patent No. 8,846,976 contains claims directed to the FDA approved dosing and daily administration of Ferric Citrate.
On September 5, 2014, Ferric Citrate was approved by the U.S. Food and Drug Administration for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. This newly issued patent further enhances the Company’s key patent family, which includes U.S. Patent Nos. 7,767,851, 8,299,298, 8,338,642, 8,609,896, 8,754,257 and 8,754,258, which expire in 2024, and U.S. Patent No. 8,093,423, which expires in 2028, before patent term extension. Each of these patents contains composition and method of use claims covering Ferric Citrate.
Find out what could be the best investor’s move when it comes to KERX by getting the complete report here or by cutting and pasting the following link in your Web browser: www.PennyStockHub.com
ABOUT US:
www.PennyStockHub.com issues momentum alerts on stocks that can provide gains to day traders.
www.PennyStockHub.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% – 200% or more.
www.PennyStockHub.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.PennyStockHub.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the www.PennyStockHub.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.pennystockhub.com/
Disclosure
www.PennyStockHub.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.
CONTACT:
Company: EGM FIRM INC.
Contact Name: Adam Heimann
Contact Email: [email protected]
SOURCE: www.PennyStockHub.com
Continue reading –
Big Board Biotech Stocks in Play This Week
